115 related articles for article (PubMed ID: 24061864)
21. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
Morita-Ogawa T; Sugita H; Minami H; Yamaguchi T; Hanada K
Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
[TBL] [Abstract][Full Text] [Related]
24. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
Garrett M; Taylor T; Mould DR; Amantea MA; Chen Y; Ingrosso A; Pithavala YK
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
[TBL] [Abstract][Full Text] [Related]
25. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
[TBL] [Abstract][Full Text] [Related]
26. Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.
Merino-Sanjuán M; Monteiro JF; Porta-Oltra B; Maestu I; Almenar D; Jiménez-Torres NV
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):457-64. PubMed ID: 21726412
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Loos WJ; de Jongh FE; Sparreboom A; de Wit R; van Boven-van Zomeren DM; Stoter G; Nooter K; Verweij J
J Clin Oncol; 2006 Apr; 24(10):1499-506. PubMed ID: 16574999
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
Minami H; Horio Y; Sakai S; Saka H; Shimokata K
Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H
J Clin Oncol; 2006 Feb; 24(4):688-94. PubMed ID: 16446342
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
35. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.
Royer B; Jullien V; Guardiola E; Heyd B; Chauffert B; Kantelip JP; Pivot X
Clin Pharmacokinet; 2009; 48(3):169-80. PubMed ID: 19385710
[TBL] [Abstract][Full Text] [Related]
39. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Kern W; Braess J; Kaufmann CC; Wilde S; Schleyer E; Hiddemann W
Anticancer Res; 2000; 20(5C):3679-88. PubMed ID: 11268439
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
